You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER4

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent/Advanced Gastric Cancer Trial in Seoul (Chemotherapy)

Not yet recruiting
  • Recurrent/Advanced Gastric Cancer
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Aug 22, 2022

HIV Prevention, Pre-exposure Prophylaxis, PrEP Trial in Chapel Hill (I'm Fully Empowered for Her (IFE4Her))

Not yet recruiting
  • HIV Prevention
  • +5 more
  • I'm Fully Empowered for Her (IFE4Her)
  • Chapel Hill, North Carolina
    University of North Carolina
Jan 27, 2023

HR+/HER2-breast Cancer Trial (Standard endocrine therapy plus Apatinib)

Not yet recruiting
  • HR+/HER2-breast Cancer
  • Standard endocrine therapy plus Apatinib
  • (no location specified)
Jun 2, 2023

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;

Recruiting
  • Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
  • dalpiciclib; fluvestrant; compound gossypol acetate tablets
  • Hangzhou, Zhejiang, China
    zhejiangCH
Nov 9, 2023

Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago

Not yet recruiting
  • Estrogen-receptor-positive Breast Cancer
  • +3 more
  • elacestrant, palbociclib, abemaciclib, ribociclib
  • Chicago, Illinois
    Northwestern University
Sep 25, 2023

CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent

Not yet recruiting
  • Breast Cancer
  • +3 more
  • Different treatment regimens following progression on CDK4/6 inhibitors.
  • (no location specified)
Sep 5, 2023

Breast Tumor Female Trial in Beijing (CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou))

Recruiting
  • Breast Neoplasm Female
  • CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)
  • Beijing, Beijing, China
  • +1 more
Jul 31, 2023

Advanced HR+ HER2 Negative Breast Carcinoma Trial ((CDK)4/6 inhibitor)

Not yet recruiting
  • Advanced HR+ HER2 Negative Breast Carcinoma
  • (CDK)4/6 inhibitor
  • (no location specified)
Sep 27, 2022

Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide combined with fulvestrant)

Not yet recruiting
  • Hormone Receptor-positive Advanced Breast Cancer
  • chidamide combined with fulvestrant
  • (no location specified)
Mar 28, 2023

Breast Cancer Trial (RP-6306, Gemcitabine, Observation)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Jan 26, 2023

Locally Advanced Breast Cancer, Hormone Receptor Positive,HER2-negative Breast Cancer Trial in Jinan (letrozole)

Recruiting
  • Locally Advanced Breast Cancer
  • Hormone Receptor Positiveļ¼ŒHER2-negative Breast Cancer
  • Jinan, Shandong, China
    Breast Cancer Center, Shandong Cancer Hospital and Institute
Apr 11, 2023

Health Knowledge, Attitudes, Practice, Alcohol Drinking Trial in Ringwood East (Brief alcohol intervention

Not yet recruiting
  • Health Knowledge, Attitudes, Practice
  • Alcohol Drinking
  • Brief alcohol intervention (Health4Her-Automated)
  • Lifestyle health promotion
  • Ringwood East, Victoria, Australia
    Maroondah BreastScreen
Aug 30, 2023

Metastatic Cancer, HER2 Gene Mutation Trial in Seoul (Neratinib Maleate)

Active, not recruiting
  • Metastatic Cancer
  • HER2 Gene Mutation
  • Neratinib Maleate
  • Seoul, Korea, Republic of
    Korea university Guro hospital
Oct 18, 2023

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)

Not yet recruiting
  • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
  • (no location specified)
Sep 26, 2023

Concordance of IHC4 Score Performed in Local or Central

Active, not recruiting
  • Breast Neoplasm Female
  • IHC4 score
  • Nice, France
    Centre Antoine Lacassagne
Feb 2, 2023

Breast Cancer Metastatic Cancer Trial in Shanghai (Apatinib, Dalpiciclib, Fulvestrant/AI)

Recruiting
  • Breast Cancer Metastatic Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023

Breast Cancer, Advanced Breast Cancer Trial in Shanghai (Everolimus 10 mg, CDK4/6 Inhibitor SHR6390, Aromatase inhibitor and

Not yet recruiting
  • Breast Cancer
  • Advanced Breast Cancer
  • Everolimus 10 mg
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 14, 2023

Breast Cancer Metastatic Cancer Trial in Shanghai (Fluzoparib, Dalpiciclib, Fulvestrant/AI)

Recruiting
  • Breast Cancer Metastatic Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023

Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer Trial (OP-1250, Fulvestrant, Anastrozole)

Not yet recruiting
  • Breast Cancer
  • +4 more
  • (no location specified)
Aug 31, 2023

HR+/HER2- Advanced Breast Cancer Trial in Beijing (Dalpiciclib, Chidamide)

Not yet recruiting
  • HR+/HER2- Advanced Breast Cancer
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
Oct 17, 2022

Breast Cancer Trial in Tianjin (Dalpiciclib, Pyrotinib, Fulvestrant)

Not yet recruiting
  • Breast Cancer
  • Tianjin, China
    Tianjin Cancer Hospital
Mar 28, 2023

Cyclin-dependent Kinase 4/6 Inhibitors on Body Composition in

Recruiting
  • Breast Cancer
  • CT scans
  • DEXA scan
  • Bronx, New York
    Montefiore Medical Center
Jan 6, 2023

Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023

Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide,fulvestrant)

Not yet recruiting
  • Hormone Receptor-positive Advanced Breast Cancer
  • (no location specified)
Apr 12, 2023

Metastatic Breast Cancer Trial (Elacestrant)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Oct 24, 2022